Literature DB >> 25936965

Development of a novel cell-based assay to monitor the transactivation activity of the HSV-1 protein ICP0.

Angela M Fowler1, Heather E Shinogle2, David J Davido3.   

Abstract

The herpes simplex virus type 1 (HSV-1) immediate-early phosphoprotein infected cell protein 0 (ICP0) is a potent transcriptional activator of viral genes and is required for efficient viral replication and reactivation from latency. However, it is largely unknown what role specific cellular factors play in the transactivator function of ICP0. With the long-term goal of identifying these factors, we developed a cell-based assay in a 96-well format to measure this activity of ICP0. We designed a system using a set of HSV-1 GFP reporter viruses in which the expression of GFP is potently induced by ICP0 in cell culture. The initial feasibility of this system was confirmed over a 24-h period by fluorescence microscopy. We adapted this assay to a 96-well plate format, quantifying GFP expression with a fluorescence scanner. Our results indicate that the cell-based assay we developed is a valid and effective method for examining the transactivating activity of ICP0. This assay can be used to identify cellular factors that regulate the transactivating activity of ICP0.
Copyright © 2015 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Cell-based assay; GFP; HSV; ICP0; Viral transcription

Mesh:

Substances:

Year:  2015        PMID: 25936965      PMCID: PMC4492837          DOI: 10.1016/j.antiviral.2015.04.012

Source DB:  PubMed          Journal:  Antiviral Res        ISSN: 0166-3542            Impact factor:   5.970


  33 in total

1.  N-terminal phosphorylation sites of herpes simplex virus 1 ICP0 differentially regulate its activities and enhance viral replication.

Authors:  Heba H Mostafa; Thornton W Thompson; David J Davido
Journal:  J Virol       Date:  2012-12-05       Impact factor: 5.103

2.  The herpes simplex virus type 1 regulatory protein ICP0 enhances virus replication during acute infection and reactivation from latency.

Authors:  W Cai; T L Astor; L M Liptak; C Cho; D M Coen; P A Schaffer
Journal:  J Virol       Date:  1993-12       Impact factor: 5.103

3.  The herpes simplex virus immediate-early protein ICP0 affects transcription from the viral genome and infected-cell survival in the absence of ICP4 and ICP27.

Authors:  L A Samaniego; N Wu; N A DeLuca
Journal:  J Virol       Date:  1997-06       Impact factor: 5.103

4.  Construction and characterization of herpes simplex virus type 1 mutants with defined lesions in immediate early gene 1.

Authors:  R D Everett
Journal:  J Gen Virol       Date:  1989-05       Impact factor: 3.891

5.  Herpes simplex virus type 1 immediate-early protein Vmw110 reactivates latent herpes simplex virus type 2 in an in vitro latency system.

Authors:  R A Harris; R D Everett; X X Zhu; S Silverstein; C M Preston
Journal:  J Virol       Date:  1989-08       Impact factor: 5.103

6.  Herpes simplex virus type 1 ICP0 plays a critical role in the de novo synthesis of infectious virus following transfection of viral DNA.

Authors:  W Z Cai; P A Schaffer
Journal:  J Virol       Date:  1989-11       Impact factor: 5.103

7.  Simple resazurin-based microplate assay for measuring Chlamydia infections.

Authors:  Ichie Osaka; P Scott Hefty
Journal:  Antimicrob Agents Chemother       Date:  2013-03-18       Impact factor: 5.191

8.  Herpes simplex virus type 1 ICP0 regulates expression of immediate-early, early, and late genes in productively infected cells.

Authors:  W Cai; P A Schaffer
Journal:  J Virol       Date:  1992-05       Impact factor: 5.103

9.  The transactivating effect of HSV-1 ICP0 is enhanced by its interaction with the PCAF component of histone acetyltransferase.

Authors:  Weizhong Li; Wei Cun; Longding Liu; Min Hong; Lei Wang; Lichun Wang; Chenghong Dong; Qihan Li
Journal:  Arch Virol       Date:  2009-10-07       Impact factor: 2.574

10.  hTERT extends the life of human fibroblasts without compromising type I interferon signaling.

Authors:  Miles C Smith; Erica T Goddard; Mirna Perusina Lanfranca; David J Davido
Journal:  PLoS One       Date:  2013-03-05       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.